Physician profile
Ronald Andrews
NPI 1083699946
$591.46
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $295 · 2020: $146 · 2021: $151.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $149.88 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $108.60 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $68.62 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $63.69 | 2019-2020 | |
| Novo Nordisk INC | $54.53 | 2020-2021 | |
| Endo Pharmaceuticals INC. | $30.51 | 2019-2020 | |
| Lilly USA, LLC | $27.26 | 2019-2020 | |
| Ironshore Pharmaceuticals INC. | $17.98 | 2019 | |
| Shire North American Group INC | $17.04 | 2019 | |
| Sobi, INC | $16.40 | 2020 | |
| Arbor Pharmaceuticals, INC. | $12.59 | 2019 | |
| Sanofi-Aventis U.S. LLC | $12.56 | 2020 | |
| Horizon Therapeutics Plc | $11.80 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ronald Andrews listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.